Description of changes in cholesterol and blood pressure lowering medication
There were no changes in cholesterol-lowering treatment during the study, except for two LCD participants who reported sporadic use of statins. In the LCD-group, one patient treated with both an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) had the ACE inhibitor discontinued. Another patient in the LCD group discontinued thiazide treatment and was reduced in beta-blocker treatment. In two other patients in the LCD group, the dose of ARB treatment dose reduced (25 mg and 50 mg, respectively) due to orthostatism. In one patient in the control group, the dosage of ACE inhibitor combined with hydrochlorthiazide was increased.